Fluoxetine (Prozac) and other serotonin reuptake inhibitors (SSRI’s) increase the risk of suicide. The Boston Globe wrote an article talking about this in 2000. The article noted that…
“Lilly’s own figures, in reports made available to the Globe, indicate that 1 in 100 previously nonsuicidal patients who took the drug in early clinical trials developed a severe form of anxiety and agitation called akathisia, causing them to attempt or commit suicide during the studies.”
The article later notes that:
“Yet the problems with Prozac were known even before it was introduced to the US market. Figures in a 1984 Lilly document indicated that akathisia, the severe agitation that can lead to suicide, occurs in at least 1 percent of patients, a level considered a “frequent” event, and as such must be disclosed in a company’s product literature and package inserts. But there is no such disclosure in Prozac’s US literature, and it is not clear whether the FDA panel charged with approving Prozac simply overlooked or did not have access to certain critical data of Lilly’s.
“As a result, researchers say that most US doctors do not know to warn patients of the potentially dangerous effect which, according to published literature on the topic, can be alleviated with sedatives or by going off the drug.
“German regulators, who eventually approved Prozac for use in that country, require a warning label about the risk of suicide and suggest the concurrent use of sedatives when necessary.
“Akathisia is listed in Lilly’s US product literature, but as an infrequent event in Prozac users. No mention is made of its potential relationship to suicide.”
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.